By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


OncoSec Medical Inc. 

200 South Virginia Street
8th Floor
Reno  Nevada  89501  U.S.A.
Phone: 775-562-0504 Fax: n/a


Medical Device

Company News
OncoSec Medical Announces Technology Access Program Agreement With Jounce (JNCE) 6/12/2017 8:13:27 AM
OncoSec Medical Granted Orphan Drug Designation From The U.S. FDA For The Treatment Of Unresectable Metastatic Melanoma 6/9/2017 7:30:23 AM
OncoSec Medical Announces Third Quarter And YTD Results For Fiscal Year 2017 6/2/2017 7:18:44 AM
OncoSec Medical To Host Third Quarter Financial Conference Call On June 1, 2017 5/11/2017 9:18:43 AM
OncoSec Medical Announces Clinical Collaboration With Merck & Co. (MRK) To Evaluate Combination Of Immunopulse IL-12 And KEYTRUDA (Pembrolizumab) For Metastatic Melanoma 5/10/2017 6:54:44 AM
OncoSec Medical Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response Following Modifications To IL-12 Gene Delivery Therapy At AACR Annual Meeting 4/3/2017 9:44:58 AM
OncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness At Enhancing Tumor Immunogenicity In Preclinical Tumor Models 3/22/2017 7:20:27 AM
OncoSec Medical Announces Second Quarter And YTD Results For Fiscal Year 2017 3/17/2017 8:40:50 AM
OncoSec Medical Announces First Technology Access Program Agreement With Inhibrx 3/14/2017 8:55:19 AM
OncoSec Medical Granted FDA Fast Track Designation For Immunopulse IL-12 For The Treatment Of Metastatic Melanoma Following Progression On Pembrolizumab Or Nivolumab 2/27/2017 6:27:44 AM